COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02512237
Recruitment Status : Terminated (Replace with a new trial)
First Posted : July 30, 2015
Last Update Posted : June 5, 2020
Ambrx, Inc.
Information provided by (Responsible Party):
Zhejiang Medicine Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 2017